Field Trip Health Ltd. Applies to List Its Common Shares on the NASDAQ Stock Market
Field Trip Health Ltd. (TSX: FTRP; FTRP.WT; OTCQX: FTRPF) (“Field Trip”), a leader in the development and delivery of psychedelic therapies, is pleased to announce that it has applied to list its common shares (the “Common Shares”) on the NASDAQ Stock Market (“NASDAQ”). “Psychedelics stand poised to disrupt modern psychiatry, and the NASDAQ is where […]
Tryp Therapeutics to Present at the Ladenburg Thalmann Healthcare Conference
San Diego, California–(Newsfile Corp. – June 8, 2021) – Tryp Therapeutics (CNSX:TRYP.CN) (OTCQB:TRYPF) (FSE:8FW) (“Tryp”), a pharmaceutical company focused on developing compounds for diseases with unmet medical needs through accelerated regulatory pathways, announced today that it is presenting at the Ladenburg Thalmann Healthcare Conference. The conference will be held virtually on July 13 and 14. Greg McKee, […]
HAVN Life Announces Retail Partnership with Grocer, Choices Markets
Newly-launched line of natural health products to be available at all locations later this month VANCOUVER, BC / ACCESSWIRE / June 8, 2021 / HAVN Life Sciences Inc. (CNSX:HAVN.CN) (OTCPINK:HAVLF) (FSE:5NP) (the “Company” or “HAVN Life”), a biotechnology company pursuing standardized extraction of psychoactive compounds and the development of natural health products, is pleased to announce it has secured […]
Revive Therapeutics Partners with Supriya to Pursue EUA for Bucillamine to Treat COVID in India
Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF, Frankfurt: 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce it has entered into a memorandum of understanding dated June 7, 2021 with Supriya Lifescience Ltd. (“Supriya”), a specialty […]
Mydecine Discovers Over 40 Groundbreaking Potential Pharmacologically Active Novel Compounds in Mushrooms
Mydecine Innovations Group (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for mainstream use, announces that the Mydecine R&D team has made groundbreaking advances in psilocybin research with the discovery of over 40 compounds with pharmacological potential in […]
